Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Philip Coombes

Equity Research Analyst

Philip Coombes portrait

Coverage

TrygSkjern BankDanske BankNorth MediaFøroya BankiD/S NordenSJF BankAsetekNTG Nordic Transport GroupBooztSKAKOMT Højgaard HoldingSP GroupHafniaFlügger GroupRoblonAscelia PharmaXplora TechnologiesRTXVestjysk BankNetcompany GroupErriaGrønlandsbankenTormDFDSCurasightBioPortoGubraExpreS2ion Biotech HoldingGabriel Holding

Latest content

ShowingAll content types

BioPorto (Investment Case): Executing on the Forward strategy with adult pre-submission filed in Q1 2026

Research 01.04.2026 klo 17.37 by Philip Coombes, Michael Friis
BioPorto

Flügger Q3'2025/26: Poland delivers again as Nordic core demand grows under the surface

Research 20.03.2026 klo 09.59 by Philip Coombes, Rasmus Køjborg
Flügger Group

Hafnia (Investment Case): Strong cash flow and dividends in the face of geopolitical uncertainty

Research 09.03.2026 klo 17.36 by Philip Coombes
Hafnia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Gubra (One-pager): Enters 2026 with three differentiated obesity candidates — pivotal data readouts expected in 2026

Research 09.03.2026 klo 09.29 by Philip Coombes, Michael Friis
Gubra

TORM (One-pager): Leading product tanker operator with strong cash generation

Research 06.03.2026 klo 13.49 by Philip Coombes, Rasmus Køjborg
Torm

North Media (One-pager): FY2025 Cash generation underpins value in a structurally declining market

Research 04.03.2026 klo 13.53 by Philip Coombes, Rasmus Køjborg
North Media

ExpreS2ion Biotech - Intention to carry out rights issue to fully fund Phase 1 trial

Analyst Comment 02.03.2026 klo 18.52 by Philip Coombes
ExpreS2ion Biotech Holding

Gubra FY2025 – Clinical progress the focus in 2026 after record year with AbbVie partnership

Analyst Comment 27.02.2026 klo 13.20 by Philip Coombes
Gubra

NORDEN (One-pager): Asset-flexible shipping generating strong ROIC through cycles

Research 26.02.2026 klo 14.05 by Philip Coombes, Rasmus Køjborg
D/S Norden

ExpreS2ion Biotech (One-pager): Progress continues on both pipeline and partner driven programs

Research 25.02.2026 klo 15.19 by Philip Coombes, Michael Friis
ExpreS2ion Biotech Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.